PMID: 6110038Feb 21, 1981Paper

Cytotoxic monoclonal antibody to a human leiomyosacoma

Lancet
C DengL Lagasse

Abstract

A monoclonal antibody produced by the hybridoma technique against a human leiomyosarcoma was highly cytotoxic in dilutions of 1:64 000 to the original tumour cells. The antibody was unreactive with most normal cells (lymphocytes, 120 donors; spleen cells, 73/75; monocytes, 16; granulocytes, 25; platelets, 12; red cells, 11) and could not be absorbed out by smooth muscle from the small intestine or by spleen cells. Its specificity for the tumour was high since it did not react with cells from 40 patients with leukaemia, from 8 patients with other tumours, and from 7 cultured tumour lines. The only other cell that it reacted with (at 1:4000 dilution) was line 8402, a T acute lymphocytic leukaemia line. This monoclonal antibody may be suitable for therapeutic trials.

References

Jul 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·H KoprowskiM Herlyn
Mar 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·M HerlynH Koprowski
Oct 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·W G DippoldL J Old

❮ Previous
Next ❯

Citations

Jul 15, 1986·International Journal of Cancer. Journal International Du Cancer·O BrulandA Pihl
Jun 1, 1982·Cancer Treatment Reviews·C S Foster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.